|
DSP-2230 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/phase II clinical trials.〔〔 ==See also== * Raxatrigine * Funapide * PF-05089771 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「DSP-2230」の詳細全文を読む スポンサード リンク
|